Medscape August 29, 2025
A new over-the-counter product cleared by the FDA combines a continuous glucose monitor (CGM) with an artificial intelligence (AI)-based app to assist users in weight management.
The Signos Glucose Monitoring System was cleared by the FDA on March 21, 2025, and announced by the company on August 20, 2025. The system receives data from an integrated CGM (Dexcom Stelo) that measures, records, analyzes, and displays glucose data values. It is intended for people aged 18 years or older who are not using insulin. The platform can be synched with Apple Health, Google Health Connect, smartwatches, and smart scales.
According to the FDA, in addition to detecting high, low, and normal glucose values, the Signos system “may also help the user...
Today's Sponsors
Today's Sponsor